FGC
APLS

Financial Gravity Companies’s Apellis Pharmaceuticals APLS Stock Holding History

Financial Gravity Companies’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$1.73K Buy
+100
New +$1.85K ﹤0.01% 765
2024
Q4 		$3.19K Hold
100
– – ﹤0.01% 715
2024
Q3 		$2.88K Buy
+100
New +$3.7K ﹤0.01% 464

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Financial Gravity Companies's APLS Position: Q2 2025 in Review

Financial Gravity Companies opened a new position in Apellis Pharmaceuticals (APLS) in Q2 2025: 100 shares worth $1.73K. The stake represents ﹤0.01% of the portfolio and ranks #765 among its holdings. This is a return to the name: Financial Gravity Companies previously reported a position in APLS as recently as Q4 2024.

Financial Gravity Companies first reported a position in APLS in Q3 2024 and has held it in 3 quarters since. The position peaked at $3.19K in Q4 2024. 247 funds tracked by Wall St. Rank hold APLS as of Q2 2025.

  • Financial Gravity Companies held 100 shares of Apellis Pharmaceuticals worth $1.73K as of Q2 2025.
  • Apellis Pharmaceuticals was a new Financial Gravity Companies position in Q2 2025.
  • Apellis Pharmaceuticals made up ﹤0.01% of Financial Gravity Companies's portfolio in Q2 2025, its #765 holding.
  • Financial Gravity Companies first reported a position in Apellis Pharmaceuticals in Q3 2024 and has held it in 3 quarters since.
  • Financial Gravity Companies's Apellis Pharmaceuticals position peaked at $3.19K in Q4 2024.
  • 247 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2025.

Based on Financial Gravity Companies's 13F filing for Q2 2025, filed 8 Aug 2025.